Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Advaxis Scientists Publish Research of Listeria Monocytogenes-Based Vaccine for Prostate Cancer in Latest Edition of Cancer Immunology & Immunotherapy
March 18th, 2008
Drs. Vafa Shahabi (Advaxis Inc. OTCBB: ADXS) and Yvonne Paterson (University of Pennsylvania) led a team (the "Team") of six leading research microbiologists and published findings on the potential use of a Listeria monocytogenes-based vaccine for prostate cancer ("pCa"). The Team developed and characterized a recombinant live attenuated Listeria monocytogenes/PSA ("Lm-LLO-PSA") vaccine with potential use for the treatment of pCa. Results indicated that Lm-LLO-PSA is a likely candidate for pCa immunotherapy. "The Team's findings support the opportunity for immunotherapy in treating prostate cancer," said Thomas Moore chairman and chief executive...
Source: Cancer Weekly (2008-03-18)
|
